Summary - Funding Rounds

Founding Date

1996
Skyepharma is a subsidiary of Vectura Group

Skyepharma Income Statement

Annual

GBPFY, 2013FY, 2014FY, 2015

Revenue

62.6m73.8m95.9m

Revenue growth, %

18%30%

Cost of goods sold

33.2m32.9m43.1m

Gross profit

29.4m40.9m52.8m

Gross profit Margin, %

47%55%55%

Skyepharma Ratios

GBPFY, 2013